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Despite marked improvement in the prognosis of patients with nonmetastatic Ewing sarcoma (ES), the outcome for patients with
recurrent or metastatic disease remains poor. Insight into key biologic processes in ES could provide new therapeutic targets. The
particular biologic feature of ES, the fusion of the EWS gene with a member of the ETS family of genes, is present in >95% of cases.
The EWS-ETS chimeric protein leads to aberrant transcription that promotes tumor initiation and propagation via prosurvival
and antiapoptotic pathways. Recent research has identiﬁed cooperating mutations important for ES tumorigenesis. This paper
provides a summary of the latest research in ES and discusses potential novel targets for therapy.
1.Introduction
Ewing sarcoma is the second most common malignant bone
tumor in children and adolescents. The tumor consists of
small blue round cells and is characterized by a translocation
between EWS and a member of the ETS transcription factor
family. The translocation is also found in Askin’s tumor,
extraosseous Ewing sarcoma (EES), and peripheral primitive
neuroectodermal tumors (pPNETs) which together with
Ewing sarcoma comprise the Ewing sarcoma family of
tumors (EFST), in the following referred as Ewing sarcoma
(ES).TheannualincidenceofESisthreein1millionchildren
under 15 years with 30% of patients presenting with meta-
stases to the lungs, bone, or bone marrow at diagnosis [1].
Owing to multicenter clinical trials, the survival for patients
with ES, especially patients with localized disease has
improved over the past decades with the application of sys-
temic chemotherapy in conjunction with either surgery or
radiation therapy or both for local tumor control. Currently,
the 5-year overall survival in patients with localized ES is
approximately 70%; however, this rate has plateaued over the
past ten years. The prognosis of children and young adults
with metastatic or recurrent disease is grim with less than
one-third of patients with metastases at diagnosis and only
10% of patients with recurrent disease being long-term
survivors [2, 3].
Unfortunately, the lack of survival gains over the last ten
yearsforthesehighriskpatients’groupssuggeststhatfurther
improvements in outcome with classic chemotherapy maybe
limited.Newtargetedantineoplasticagentsbasedondetailed
insights into the biology of ES are needed.
ThepathognomonicgeneticmarkerofESistherecurrent
translocation involving the EWS locus on chromosome 22
band q12. In the majority of cases (85% to 90%), the amino
terminus of EWS is juxtaposed with the carboxy terminus of
FLI1, a member of the ETS family of transcription factors
which is coded by a gene located on chromosome 11 band
q24 [4]. To a lesser extent, other ETS family members that
combine with the EWS gene include ERG (chromosome 21),
ETV1 (chromosome 7), and E1AF (chromosome 17) [5, 6].
The fusion of EWS with an ETS family member results in
an aberrant transcription factor, altering cellular functions,
and signalling pathways leading to improved survival, loss of
diﬀerentiation, and proliferation. The cellﬁrst expressing the
fusion transcript and responsible for tumor formation is a
matter of debate, however, gene expression analysis suggests
mesenchymal stem cells to be the cell of origin of ES [7].
Besides the translocation involving the EWS gene, additional
numerical and structural aberrations have been observed in
ES,includingwholeaswellaspartialchromosomalgainsand
losses[8].Theselattergeneticchangeswillnotbefurtherdis-
cussedinthispaper.WewillfocusontheeﬀectsofEWS-FLI12 ISRN Oncology
onapoptotic-andsurvivalpathwaysandpossibletherapeutic
targets.
2. EWS-FLI1
The t(11; 22)(q24; q12) chromosomal translocation that
fuses the EWS gene to the FLI1 gene was ﬁrst identiﬁed
almost 20 years ago. The precise cellular mechanism by
which EWS-FLI1 leads to ES still remains to be determined.
The fusion protein product of EWS-FLI1 preferentially binds
to consensus ETS motifs and GGAA repeat microsatellite
sequences. These binding sites are outside of the promoter
regions and located up to more than 5kb upstream of the
regulated genes [9]. EWS-FLI1 lacks a stable structure and
contains a high proportion of disordered regions which
facilitates interaction with a number of transcription factors
as well as ease binding and dissociation from nuclear protein
complexes to alter cellular transcriptional activities [10].
Moreover, direct protein interaction has been observed
between EWS-FLI1 and RNA polymerase II, CREB-binding
protein, BARD1, NROB1 and RNA Helicase A (RHA) [10–
12]. The sum eﬀect of binding of EWS-FLI1 to cellular com-
ponents is threefold: (1) induction of transcription of genes
involved in cell cycle regulation and DNA repair, (2) repres-
sion of expression of genes involved in cell adhesion, migra-
tion and homing such as integrin-, polysaccharide-, and
glycosaminoglycan- or heparin-binding proteins, and (3)
altered expression of several apoptotic genes (Figure 1)[ 11–
13].
Because EWS-FLI1 lacks enzymatic activity, recent
researchinEStherapy,hastargetedthedisruptionofprotein-
protein interactions of EWS-FLI1 and its binding partners.
Erkizan et al. demonstrated that direct interaction between
EWS-FLI1 and RHA, was crucial for EWS-FLI1- induced
transformation of mouse embryonic ﬁbroblasts. After
screening 3,000 small molecules from the NCI Drug Target-
ingProgram,onesmallmolecule,YK-4-279,whichinhibited
the interaction between EWS-FLI1 and RHA was identiﬁed.
YK-4-279 induced the activation of caspase-3 and apoptosis
in ES cell lines and inhibited tumor growth in an ES xeno-
g r a f tm o d e lb u tn o ti nm a l i g n a n tn o n - EWS-FLI1-expressing
cells[14].AnothermodulatorofEWS-FLI1 activity,however,
did not prove to be eﬀective in ES patients. Cytarabine,
an antimetabolite antineoplastic agent, reduced EWS-FLI
protein abundance in ES cells, diminished cell viability in
vitro and abrogated tumor growth in a xenograft model by
inducing apoptosis and inhibiting anchorage independent
growth [15]. In a phase II study, administration of inter-
mediate dose cytarabine to ten patients failed to show any
antitumor activity. Another trial did not ﬁnd any beneﬁt for
the three ES patients treated with low dose cytarabine [16].
3. EWS-FLI1, TP53, RB SignallingPathway,
andCDKs
Early investigations of EWS-FLI1-induced transformation of
mouse embryonic ﬁbroblasts (MEFs) revealed that not all
ﬁbroblasts were equally susceptible to transformation. Over-
expressionofEWS-FLI1innormalMEFresultedinapoptosis
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Figure 1: Interaction of EWS-FLI1 with transcription factors
(green). Examples of induced target genes are red, suppressed
genes are blue. Alteration of gene expression by EWS-FLI1 leads
to suppression of apoptosis and enhancement of proliferation and
migration.
and growth arrest [17, 18]. In contrast, transformable MEFs
lacked components of the G1 checkpoint, that is, p16ink4 or
tp53, favoring stable expression of EWS-FLI1 to hinder apo-
ptosis. When injected with EWS-FLI1-transduced MEF, only
two of eight SCID mice developed tumors, suggesting that
further cooperating genetic events are required for tumori-
genesis in this experimental system [18].
In human neonatal foreskin ﬁbroblasts growth arrest
induced by stable expression of EWS-FLI1 was a result of
TP53-upregulation and independent of alterations of the
p16-RB pathway. Inhibition of TP53 bypassed an early
growth arrest. Nevertheless additional EWS-FLI1-induced
growthinhibitorypathwayshavetobesuppressedinorderto
transform human ﬁbroblasts. Even in transformed cells
expressing E6, E7, SV40, and RASV12 induction of EWS-FLI1
inhibits colony formation. The characterization of these
additional inhibitory pathways induced by EWS-FLI1 is
pending. The independence of EWS-FLI1-induced growth
arrestfromp16 pathwaysin this cellularbackground empha-
sizes the importance of careful interpretation of results in
diﬀerent cellular model systems [19]. By contrast, expression
of EWS-FLI in murine bone-marrow-derived mesenchymal
progenitor cells in the presence of functional tp53 generated
tumorsthatdisplayedhallmarksofES,providingacluetothe
potential origin of ES [7, 17]. The basis for the susceptibility
of these mesenchymal cells to transfection is currently focus
of intensive research.
New data show direct interaction of EWS-FLI1 N-
Terminal Domain with TP53 protein in the nucleus and
binding ofthis complextothepromotors of P21andMDM2,
inhibiting their expression [20]. Another study using
TP53wt ES cell lines showed that disruption of NOTCH sig-
nalling by EWS-FLI1 through repression of JAG1 led to
repression of TP53 and downstream P21-mediated cell cycleISRN Oncology 3
arrest.Inaddition,inhibitionoftheNOTCHsignallingpath-
way by EWS-FLI1 might suppress terminal diﬀerentiation in
the ES precursor cell which could promote transformation
and tumor growth [21].
While mutations or deletions of a cell cycle checkpoint
gene such as TP53 and CDKN2A are commonly encountered
in many tumor types, in ES, speciﬁc mutation or deletion of
these genes are rare events [22]. For example, most ES have
TP53wt and only 5% to 20% harbor deletions or point
mutations of TP53, 30% show deletions of p16INK4 [18, 23].
Aberrations of TP53 or p16INK4/p14ARF, although rare, are
associated with decreased overall survival and have been the
strongest negative predictor of outcome in ES, even more
than the presence of metastases at diagnosis in multivariate
analysis [22]. The apparent contradiction between rare TP53
mutations and data suggesting a need of inhibition of the
TP53 pathway to transform the cell of origin is yet not solved
but could serve as a clue to understand the initial steps in
development of ES.
In addition to TP53 inhibition, EWS-FLI1 induces over-
expression of CDKs in ES cells. Since inhibition of CDKs has
been shown to trigger apoptosis via the intrinsic pathway in
various tumor models, CDK may present a potential target
for therapy in ES [12]. Tirado et al. found that roscovitine,
a purine analog and potent CDK inhibitor, was a highly
eﬃcient inducer of apoptosis in TP53mut ES cells via TP53-
independent upregulation of the proapoptotic protein BAX
anddownregulationofsurvivinandXIAPleadingtocaspase-
3a n dc a s p a s e - 7a c t i v a t i o n[ 24]. Likewise, Li et al. treated
WE-68, a TP53wt ES cell line, with ﬂavopiridol, a pan CDK
inhibitor which induced TP53, resulting in an increase of
BAX/BCL-2 ratio and the release of mitochondrial cyto-
chrome c and the activation of caspase-9, caspase-8, and
caspase-3 and apoptotic cell death [25].
4.BCL-2,IAPs,andSmac/DIABLO
Based on the observation that expression of EWS-FLI1 in
nontransformed primary cells results in apoptosis and that
ES cell lines are exquisitely chemosensitive, changes in ratios
ofpro-andantiapoptoticmemberslikeBAX/BAK,BH3-only
proteins (i.e., BID, BAD, Puma, NOXA) and BCL-2/BCL-XL
in ES may be supposed. Gene expression analysis showed
that although the majority of genes regulated by EWS-FLI1
belong to cell cycle control and diﬀerentiation pathways,
some apoptotic genes like BCL11B (antiapoptotic-induced),
GADD45A (proapoptotic-repressed), CAD (execution of
apoptosis–induced), DAPK1 (proapoptotic-induced), BAG3
(antiapoptotic-repressed), DBB2 (proapoptotic-induced),
and Caspase-3 (proapoptotic-induced) are also regulated.
Detailed functional studies of most of these factors in ES cell
lines are lacking [12]. Similar to the above-mentioned anal-
ysis of cell cycle control in diﬀerent cellular model systems,
the EWS-FLI1 expression pattern and its eﬀects on apoptosis
are likely to be cell type-dependent, as well. In cellular
model systems which are only partially comparable to the
cell of origin, the accumulation of proapoptotic factors like
caspase-3 leads to initiation of apoptosis in case of EWS-FLI1
expression [26]. This intriguingly raises the question why the
mesenchymal stem cell is resistant to the apoptotic stimuli
mediated by EWS-FLI1 expression: the answer may help to
identify new therapeutic targets. IAP (inhibitors of apopto-
sis)suchasSmac/DIABLOinEShavegarneredlessattention.
There has been only one study, analysing primary tumour
tissues, which reports the expression of Smac/DIABLO in the
cytoplasm of one of two primary ES tumor samples [27].
5.DeathLigandsandReceptors
Apoptosis via death receptors serves as the principal pathway
inimmune-mediatedantitumourresponseandrepresentsan
attractive target for therapy. In susceptible cells, interaction
of a death ligand with its corresponding death receptor leads
to formation of DISC (death-induced signalling complex)
and direct high level of activation of caspase-8 and down-
stream eﬀector caspases (type I cells). In cells with only low
levels of activated caspase-8 generated (type II cells), activa-
tion of downstream caspases is mediated via the mitochon-
drial loop after cleavage of BID, a BH3 domain contain-
ing BCL-2 family protein, by caspase-8 [28]. FAS-FASL-,
and DR4-/DR5-TRAIL- (TNF-related apoptosis-inducing
ligand)-induced apoptosis represent prototypical apoptotic
signalling pathways (Figure 2)[ 29]. Although FAS and FASL
are expressed in a wide range of ES cell lines, most ES cell
lines are not sensitive to FAS-induced apoptosis. Additional
inhibition of antiapoptotic factors by cycloheximide or
upregulation of proapoptotic factors such as by IFN-γ are
often required for FAS-mediated apoptosis in ES cells [30].
Deregulation of BCL2 family members may be responsible
for this resistance as FAS-sensitive cell lines had a higher
expression of the proapoptotic protein BAD and lower levels
of the antiapoptotic protein BAR [31]. In contrast to the
inconsistent sensitivity to FAS-mediated apoptosis in ES
cells, TRAIL induces apoptosis in about 80% of ES cell lines
expressing the corresponding DR4 and DR5 death receptors
invitro[32,33].Nevertheless,afractionofEScellsisresistant
to TRAIL-induced apoptosis by virtue of low or absent
expression of caspase-8 and subsequent inhibition of the
downstream apoptotic cascade [34]. Interestingly, caspase-8
may be upregulated by interferon-γ (IFN-γ) via the STAT1
pathway, to render previously resistant cells susceptible to
TRAIL [3, 35]. Concentrations of IFN-γ required for TRAIL
induced apoptosis in these ES cells were as low as 20U/mL;
an amount fourfold lower than concentrations found in sera
of patients treated with IFN-γ for other diseases [34].
Eﬀorts to demonstrate an antitumor eﬀect of TRAIL
in vivo, however, have not been successful to date. In an
orthotopic ES mouse xenograft model, TRAIL demonstrated
only moderate antitumor activity in primary tumors, but
hadnoeﬀectonmetastases.Combinedtherapywithdoxoru-
bicin,whichhasbeenshowntoinduceDR4andDR5inrenal
cell carcinoma cells, did not improve eﬃcacy. Mechanisms
involved in TRAIL resistance in this model are yet not clear.
In addition to other changes in TRAIL signalling, downreg-
ulation of DR4 may be important [36]. In another model,
gene delivery utilizing a cationic lipid vector led to sustained
expression of hTRAIL in tumor cells and inhibited growth of
the primary tumor and improved overall survival in mice.4 ISRN Oncology
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Figure 2: Initiation of apoptosis and death signalling through TRAIL receptors.
Unfortunately, metastases could not be evaluated due to a
low rate of metastatic lesions [37].
To overcome resistance of tumor cells to TRAIL-medi-
ated apoptosis, an increasing number of combinational ther-
apies have been investigated both in vitro and in vivo
studies. Treatment with IFN-γ and TRAIL-receptor anti-
bodies decreased metastasis formation and improved overall
survival in mice, although only a modest eﬀect on primary
tumor growth was observed [36]. Mechanisms of how and
why IFN-γ prevented metastasis are under investigation.
Another therapy showing synergistic eﬀect in two ES cell
lines was treatment with histone deacetylase inhibitors and
TRAIL [38]. Similarly, application of TRAIL and the protea-
some inhibitor bortezomib to ES cell lines resulted in cell
cycle arrest and apoptosis [39]. In a mouse model, com-
bination treatment with TRAIL and the tyrosine kinase
inhibitor imatinib reduced both the volume of primary
tumours as well as pulmonary metastases possibly due to
imatinib-induced enhancement of NK-cell sensitivity to IL-2
or IL-12 leading to increased IFN-γ release and stimulation
of TRAIL-downstream pathways. Notably, in contrast to
previous studies, treatment with TRAIL alone reduced
developmentofpulmonarymetastasesinthismodel[40,41].
Use of TRAIL as a single agent in phase I and II trials
in humans showed that the agent was well tolerated but had
limited eﬃcacy. In three phase I studies in solid tumors,
monotherapy with human monoclonal antibodies against
TRAIL receptor, demonstrated stable disease at best [42–44].
Considering that any oncologic monotherapy leads to rapid
development of therapeutic resistance, combinational ther-
apeutic approaches have been designed in order to interfere
with TRAIL resistance through modulation of the TRAIL-
signallingpathway.AphaseIbstudycombiningrecombinant
hTRAIL with paclitaxel, carboplatin, and the antivascular
endothelial growth factor A (VEGF-A) agent bevacizumab,
in patients with advanced NSCLC showed that combination
therapy was well tolerated with no dose limiting toxicities.
The authors were able to demonstrate an antitumor activity
with a 58% overall response rate [45]. Of note, variations in
the expression of DR4 and DR5 or caspase-8 in diﬀerent
tumor types, diﬀerent patients and perhaps diﬀerent cells
within one tumor have been observed. These potential lim-
itations of death ligands as antitumor agents highlight the
importance of combination regimens when using death
receptors as therapeutic targets [34].
6.The IGF-I/IGF-IRSignallingPathway
The contribution of the insulin-like growth factor (IGF)
pathway to oncogenesis in ES is widely accepted [46, 47].
Binding of IGF-I to the insulin-like growth factor I
receptor (IGF-IR) leads to activation of PI3K- and MAPK-
pathways promoting proliferation (Figure 3)[ 48]. Several
epidemiological studies suggest a link between IGF-I and ES.
The peak incidence of ES in the second decade of life and
risingIGF-Ilevelsinpubertyappeartobeafundamentalpart
of tumour initiation rather than mere co-incidence [1, 49].
Patients with metastatic disease and low IGF-I levels andISRN Oncology 5
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Figure 3: Insulin receptor, ligands and inhibitory components leading to activation of the MAPK- and PI3K- pathway. Solid lines indicate
direct interaction of participating factors, broken lines indicate ﬁnal eﬀects (i.e. activation of mTOR).
high IGFBP3:IGF-I ratios showed a trend towards improved
survival [50]. Moreover, there is data linking elevated IGF-I
blood levels to increased risk of breast, colon or prostate
cancer [48, 51]. Molecular studies have shown that (1) the
aberrant transcription driven by EWS-FLI1 leads to repres-
sionofinsulin-likegrowthfactorbindingprotein3(IGFBP3)
[52], (2) IGF-I is induced by the ES fusion protein [53]a n d
(3) in NIH3T3 cells and embryonic stem cells, in addition
to direct IGFBP3 repression, IGFBP3 expression is further
diminished by EWS-ETS repression of transforming growth
factor beta receptor type II (TGFβRII) expression. TGFβ was
shown to induce IGFBP3 and to mediate growth inhibition
in breast cancer cells [54–56].
There are preclinical and clinical studies examining the
therapeutic eﬀects of targeted therapy to IGF-IR or down-
stream components of the pathway. Induction of apoptosis
through inhibition of IGF-IR with a monoclonal antibody
was observed as early as 1990 [57–59]. Combination therapy
with classic chemotherapy agents increased apoptosis and
impaired the formation of colonies in soft agar [60]. Based
on these encouraging results, several IGF-IR antibodies have
been developed and are being tested in phase I/II studies in
ES patients. Treatment with ﬁgitumumab, an IgG2 anti-IGF-
IR-monoclonal antibody, resulted in one complete and one
partial response in a cohort of 15 ES patients. Forty percent
(n = 6) of patients had stable disease lasting from 4 to >16
months. Six patients were free of disease progression after
6 months of IGF-IR blockade [61]. Similar results were
achieved in ES patients with another IgG1 anti-IGF-IR-
antibody, R1507. Two of nine (22%) patients had a partial
response while another two patients had stable disease [62].
Although response rates are only around 25%, these results
are promising because the responses were observed with
administration of one single-agent in the setting of recurrent
disease in patients who had previously received multiple
chemotherapy courses. Indeed, future studies may beneﬁt
from molecular studies to identify patients most likely to
respond to IGF-IR-antibody therapy [63].
Other therapeutic strategies have used tyrosine kinase
inhibitors targeting members of the IGF-IR signaling path-
way. In vitro data on IGF-IR kinase inhibitors such as NVP-
AEW541, ADW742, and GSK1904529A showed induction
of apoptosis and G1 arrest in ES cell lines. Combination
therapywithvincristineordoxorubicinledtoadditiveeﬀects6 ISRN Oncology
[64–66]. NVP-AEW541 and GSK1904529A also showed
antitumor activity in xenograft tumors in mice [66, 67].
Similar results including apoptosis, G1 arrest, and inhibition
of cell migration were observed with the tyrosine kinase
signaling inhibitors, PD98059 and U0126, which inhibit
MEK/MAPK, and LY294002, which inhibits PI3K when used
in combination with chemotherapeutic drugs in vitro [68].
Silencing EWS-FLI1, which leads to inhibition of IGF-IR
expression, in combination with inhibitors of downstream
kinases, NVP-AEW541, LY294002, and PD98059, had
synergistic eﬀect on apoptosis in one ES cell line raising the
question whether direct IGF-IR blockade should be
combined with inhibition of downstream pathway players to
increase therapeutic responses [69] .m T O Rw h i c hs e r v e sa s
a target of many of tyrosine kinase pathways is of special
interest in this regard. Hyperphosphorylation of mTOR and
other downstream IGF-IR mediators like ERK and AKT
deﬁnes an unfavorable subgroup of ES patients [70]. Com-
bined inhibition of IGF-IR and mTOR by cixutumumab,
a humanized anti-IGF-IR-IgG1 monoclonal antibody and
temsirolimus led to a >20% tumor volume reduction in two
of three ES patients. An ongoing phase II clinical trial will
determine whether these results may be veriﬁed in an
expanded cohort of ES patients [71].
7.TyrosineKinasesasTargets
The groundbreaking results of tyrosine kinase inhibitor ima-
tinib in the treatment of patients with chronic myelogenous
leukemia (CML) and gastrointestinal stroma tumors (GISTs)
represent a perfect example of translating basic research into
development of new drugs. Thusly, the expression and role
of kinases have been studied in ES [72–75].
C-kit may be detected in 38–44% of primary ES tumors.
Cell lines expressing the receptor showed growth inhibition
ranging between 20 to 40% without signiﬁcant apoptosis in
vitro at clinically relevant doses of imatinib. Combination
treatment with doxorubicin and vincristine had synergistic
eﬀects with 15 to 30% apoptosis compared to controls
[76, 77]. The therapeutic value of imatinib was studied in a
phase II clinical trial by the Children’s Oncology Group and
unfortunately had disappointing results. Imatinib eﬃcacy in
24 patients with ES was low with only one partial response
observed [78, 79]. Similar to imatinib, dasatinib, a broad
spectrum tyrosine kinase inhibitor, which induces apoptosis
in ES cell lines in vitro, was not able to show any therapeutic
eﬃcacy in ES patients [80, 81]. Recently, ABT-869, a tyrosine
kinase inhibitor targeting Fms-like tyrosine kinase-3, c-
kit, VEGF-Rs and PDGF-Rs, has been shown to reduce
metastasis and spontaneous growth of ES xenografts in mice
[82, 83].
A receptor tyrosine kinase well characterized in breast
cancer is HER-2/neu. The receptor belongs to the EGF-
receptor family and activation is associated with promotion
of cell growth, inhibition of diﬀerentiation and apoptosis via
activation of PI3K, MAPK, and STAT pathways [84]. HER-
2/neu overexpression is found in a variety of ES cell lines
and in 16% of primary tumors; overexpression, however,
does not correlate with prognosis [85, 86]. Treatment of
ES cells with trastuzumab, a monoclonal antibody target-
ing HER-2/neu, inhibited cell growth in vitro. Combined
treatment with taxol but not with etoposide, doxorubicin
or 9-nitrocamptothecin had a synergistic eﬀect on growth
inhibition in vitro and in vivo [86]. However, tumor growth
in mice was only delayed suggesting that trastuzumab has
modest clinical eﬀect in ES.
Resistance to tyrosine kinase inhibition is a common
event even in a malignancy like CML, which is very sensitive
to speciﬁc inhibitors [87]. Combinational inhibition of
diﬀerent tyrosine kinases, which substitutefor each in caseof
primary and secondary resistance, might be an opportunity
tohinderdiseaseprogressionandtoimproveoverallsurvival.
Huang et al. showed that primary resistance to the IGF-IR
inhibitor, BMS-536924, was due to overexpression of EGFR
in one ES cell line. In a resistant rhabdomyosarcoma cell line,
combination of BMS-536924, with the pan-HER-2 inhibitor,
geﬁtinib, had synergistic antiproliferative and apoptotic
eﬀects [88]. The combination of diﬀerent tyrosine kinase
inhibitors could serve as a platform for future designs of
clinical trials. Moreover, combination of tyrosine kinase
inhibitors with chemotherapeutic drugs may confer additive
antitumor activity.
8. Conclusion
Expression of EWS-FLI1 in the cell of origin of ES likely
represents the decisive transformational event initiating pro-
survival, proproliferation and prometastatic pathways which
ultimately results in clinically apparent ES. Characterization
of these pathways will identify new therapeutic targets which
are required to improve survival particularly for ES patients
with metastatic and recurrent disease. This goal will most
likely be achieved by combinational inhibition of speciﬁc
prosurvival pathways in conjunction with induction of apo-
ptosis through DNA damage induced by current classic
c h e m o t h e r a p e u t i cd r u g sa sw e l la st a r g e t e da g e n t s ,s u c ha s
deathligands,tyrosinekinaseinhibitors,and/oranti-IGF-IR-
antibodies.
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